Cargando…
Comparison of botulinum neurotoxin type A formulations in Asia
RESULTS: All protein-based therapeutics, such as botulinum neurotoxin type A (BoNT/A), are potentially immunogenic and can lead to anaphylaxis, autoimmunity, or diminished or complete absence of therapeutic efficacy, especially if administered repeatedly. Therefore, the protein quantity in BoNT/A pr...
Autores principales: | Frevert, Jürgen, Ahn, Ki Young, Park, Mee Young, Sunga, Owen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039073/ https://www.ncbi.nlm.nih.gov/pubmed/30013379 http://dx.doi.org/10.2147/CCID.S160723 |
Ejemplares similares
-
Neurotoxin Impurities: A Review of Threats to Efficacy
por: Park, Je-Young, et al.
Publicado: (2020) -
Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products
por: Frevert, Jürgen
Publicado: (2015) -
Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®
por: Frevert, Jürgen
Publicado: (2012) -
Response to Commentary by W. Jost on: Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products
por: Frevert, Jürgen
Publicado: (2015) -
Botulinum neurotoxin formulations: overcoming the confusion
por: Samizadeh, Souphiyeh, et al.
Publicado: (2018)